Table 1. Demographic and baseline disease characteristics of included patients.
| Characteristics | EP | TPT | Total (N=30) | |||
|---|---|---|---|---|---|---|
| 1 line (n=24) | ≥2 lines (n=2) | Total (N=26) | ≥2 lines (n=4) | |||
| Age (years) | ||||||
| Mean (SD) | 63.6 (8.22) | 69.5 (7.78) | 64.1 (8.19) | 71.3 (2.50) | 65.0 (8.04) | |
| Range | 46–79 | 64–75 | 46–79 | 68–74 | 46–79 | |
| Gender, n (%) | ||||||
| Male | 22 (91.7) | 1 (50.0) | 23 (88.5) | 3 (75.0) | 26 (86.7) | |
| Female | 2 (8.3) | 1 (50.0) | 3 (11.5) | 1 (25.0) | 4 (13.3) | |
| Smoking status, n (%) | ||||||
| Never smoked | 2 (8.3) | 1 (50.0) | 3 (11.5) | 1 (25.0) | 4 (13.3) | |
| Sometimes smoked | 18 (75.0) | 1 (50.0) | 19 (73.1) | 3 (75.0) | 22 (73.3) | |
| Current smoker | 4 (16.7) | 0 | 4 (15.4) | 0 | 4 (13.3) | |
| ECOG score*, n (%) | ||||||
| 0 | 11 (47.8) | 1 (100.0) | 12 (50.0) | 1 (25.0) | 13 (46.4) | |
| 1 | 11 (47.8) | 0 | 11 (45.8) | 2 (50.0) | 13 (46.4) | |
| 2 | 1 (4.3) | 0 | 1 (4.2) | 1 (25.0) | 2 (7.1) | |
| TNM staging*, n (%) | ||||||
| Stage IIIA | 1 (4.5) | 0 | 1 (4.2) | 0 | 1 (3.6) | |
| Stage IIIB | 1 (4.5) | 0 | 1 (4.2) | 0 | 1 (3.6) | |
| Stage IIIC | 2 (9.1) | 0 | 2 (8.3) | 0 | 2 (7.1) | |
| Stage IVA | 7 (31.8) | 2 (100.0) | 9 (37.5) | 2 (50.0) | 11 (39.3) | |
| Stage IVB | 11 (50.0) | 0 | 11 (45.8) | 2 (50.0) | 13 (46.4) | |
*, ECOG score and TNM staging are unknown for 2 subjects. ECOG, Eastern Cooperative Oncology Group; EP, platinum/etoposide; SD, standard deviation; N, total number of patients; n, number of patients in a respective category; TNM, tumor, nodes, metastases; TPT, topotecan.